JCJean Chastre

Jean Chastre

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jean Chastre has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Charles-Edouard Luyt

    Service de Réanimation Médicale, Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France

    3 shared publications
  • Charles-Edouard Luyt

    Médecine Intensive Réanimation, Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Sorbonne-Université, Hôpital Pitié-Salpêtrière, Paris, France

    3 shared publications
  • Alain Combes

    Sorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France

    2 shared publications
  • Guillaume Hekimian

    Sorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Service de Médecine Intensive Réanimation , Paris

    2 shared publications
  • Guillaume Lebreton

    Service de Chirurgie Cardiaque et Thoracique, Institut de Cardiologie, AP-HP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France

    2 shared publications
  • Jean-Louis Trouillet

    Medical Intensive Care Unit, iCAN, Institute of Cardiometabolism and Nutrition, Hôpital de la Pitié–Salpêtrière, Assistance Publique–Hôpitaux de Paris, Université Pierre-et-Marie-Curie, Paris 6, 47, bd de l’Hôpital, 75651, Paris Cedex 13, France

    2 shared publications

Latest Publications

  • Serious Infections in the ICU: Evolving Concepts in Management and Prevention

    by Jean Chastre, Charles-Edouard Luyt, Michel Wolff

    Patients admitted to intensive care units (ICUs) are particularly susceptible to secondary hospital-acquired infections (HAIs), which are often severe, representing a major health concern worldwide. In 2017, the European Center for Disease Prevention and Control estimated that more than 2.5 million cases of HAIs occur annually in Europe, accounting for a substantial proportion of disability and premature death, not to mention the cost they represent for the health care system. In the United States, HAIs account for almost 100,000 deaths annually. Unfortunately, most of these infections are caused by difficult-to-treat pathogens, frequently resistant to many antibiotics, arguing for a continued reassessment of our current modalities of therapy and definition of better protocols. More active as well as less toxic antibacterial agents are still needed, as well as a better use of already available antimicrobial agents. This issue of Seminars in Respiratory and Critical Care Medicine includes contributions from world-renowned experts in the field of ICU-acquired infections, who have provided state-of-the-art information on important aspects of the clinical management of these dreadful diseases. The first article by Strich and Kadri includes a detailed and up-to-date review of the global epidemiology, burden, risk factors, and treatment of highly resistant gram-negative infections as they apply to the ICU population. Obviously, better knowledge of microbial etiologies of these infections, as well as an in-depth understanding of resistance mechanisms and risk factors, might allow better identification of patients at high risk of infection caused by problematic pathogens, such as multidrug-resistant (MDR) non-fermenting gram-negative bacilli (GNB), and extended spectrum β-lactamase (ESBL)-producing Enterobacteriaceae (including carbapenemase-producing GNB), and consequently, better selection of antibiotics, which often still entails use of antibiotics with suboptimal efficacy and/or toxicity profiles. Optimal antimicrobial antibiotic use is crucial in the ICU setting, especially in an era of rising antibiotic resistance and lack of new antimicrobial development. Study results indicate that 30 to 60% of antibiotics prescribed in ICUs are unnecessary, inappropriate, or suboptimal, highlighting the potential benefit of implementing antibiotic stewardship programs (ASPs). As rightly pointed out by Fierens and De Waele in second article, a team approach and the use of clinical decision support systems are important adjuncts helping clinicians to implement a strict ASP in ICU patients with severe infection. The next three articles deal with important topics that have plagued clinicians in the ICU for many years: Should we immediately start antibiotics in every patient with a clinical suspicion of sepsis? What is the role of emerging diagnostic technologies? And should we use biomarkers of bacterial infection to improve detection and treatment of infections in the ICU? While guidelines recommend prompt (i.e., within 1 hour of triage) antibiotic administration for sepsis and septic shock, the level of evidence is not as obvious as one might think in ICU patients having no signs of hemodynamic deterioration. Based on an in-depth literature review, Guery and Calandra in third article conclude that most data favor a link between the timing of the first dose of antibiotic and survival, but the advantages of early treatment must always be balanced by integrating the potential collateral damage associated with excessive use of antibiotics. As indicated by Vazquez Guillamet, Burnham, and Kollef in fourth article, new biomolecular techniques give us the possibility of rapidly detecting the causative pathogen(s) in case of infection and thus offer the potential for providing timely administration of appropriate antimicrobial therapy as well as minimizing the use of broad-spectrum antibiotics when they are not justified. However, advantages and limitations of rapid diagnostic techniques should be well understood prior to their introduction in the diagnostic workflow. Several studies have clearly shown that clinically relevant benefits are obtained only in the presence of an ASP, but not in its absence. While some biomarkers, such as procalcitonin, are well established and showed positive effects in regard to utilization of antibiotics and clinical outcomes in interventional trials, many other markers have not been appropriately studied. Thus, the final proof of an added value to clinical judgment is still lacking (see fifth article by Heilmann, Gregoriano, and Schuetz for a detailed review). Several articles in this issue provide up-to-date and very useful information regarding how to improve treatment of infections caused by difficult-to-treat microorganisms in the ICU setting. Optimizing the dosing of β-lactams in ICU patients in terms of target concentration attainment and clinical outcomes remains a challenge at the bedside, due to the altered pharmacokinetic parameters often observed in this cohort of patients. As indicated by Williams and colleagues (sixth article), alternative β-lactam dosing strategies that include prolonged infusions, guideline-based dosing, therapeutic drug monitoring, and the utilization of dose optimization software are required in many patients for ensuring optimal therapy and avoiding the emergence of resistant strains. In the seventh article, Martin-Loeches and colleagues review the epidemiology, pathophysiology, and treatment of the most serious forms of influenza infections, as well as other emerging viral infections, namely herpes simplex virus type 1 (HSV-1), Epstein–Barr virus (EBV), and cytomegalovirus (CMV). Unfortunately, our armamentarium against these viruses, although improving, is still limited. Bassetti and colleagues (tenth article), in a very thoughtful and up-to-date article, are proposing a new strategy for the empiric and targeted...


  • Aerosol Therapy for Pneumonia in the Intensive Care Unit

    by Charles-Edouard Luyt, Guillaume Hékimian, Nicolas Bréchot, Jean Chastre


  • Top Cited Papers
    Open Access

    Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials

    by Yannick Wirz, Marc A. Meier, Lila Bouadma, Charles E. Luyt, Michel Wolff, Jean Chastre, Florence Tubach, Stefan Schroeder, Vandack Nobre, Djillali Annane, et al.

    The clinical utility of serum procalcitonin levels in guiding antibiotic treatment decisions in patients with sepsis remains unclear. This patient-level meta-analysis based on 11 randomized trials investigates the impact of procalcitonin-guided antibiotic therapy on mortality in intensive care unit (ICU) patients with infection, both overall and stratified according to sepsis definition, severity, and type of infection. For this meta-analysis focusing on procalcitonin-guided antibiotic management in critically ill patients with sepsis of any type, in February 2018 we updated the database of a previous individual patient data meta-analysis which was limited to patients with respiratory infections only. We used individual patient data from 11 trials that randomly assigned patients to receive antibiotics based on procalcitonin levels (the “procalcitonin-guided” group) or the current standard of care (the “controls”). The primary endpoint was mortality within 30 days. Secondary endpoints were duration of antibiotic treatment and length of stay. Mortality in the 2252 procalcitonin-guided patients was significantly lower compared with the 2230 control group patients (21.1% vs 23.7%; adjusted odds ratio 0.89, 95% confidence interval (CI) 0.8 to 0.99; p = 0.03). These effects on mortality persisted in a subgroup of patients meeting the sepsis 3 definition and based on the severity of sepsis (assessed on the basis of the Sequential Organ Failure Assessment (SOFA) score, occurrence of septic shock or renal failure, and need for vasopressor or ventilatory support) and on the type of infection (respiratory, urinary tract, abdominal, skin, or central nervous system), with interaction for each analysis being > 0.05. Procalcitonin guidance also facilitated earlier discontinuation of antibiotics, with a reduction in treatment duration (9.3 vs 10.4 days; adjusted coefficient −1.19 days, 95% CI −1.73 to −0.66; p < 0.001). Procalcitonin-guided antibiotic treatment in ICU patients with infection and sepsis patients results in improved survival and lower antibiotic treatment duration.


  • Open Access

    Life-threatening massive pulmonary embolism rescued by venoarterial-extracorporeal membrane oxygenation

    by Fillipo Corsi, Guillaume Lebreton, Nicolas Bréchot, Guillaume Hekimian, Ania Nieszkowska, Jean-Louis Trouillet, Charles-Edouard Luyt, Pascal Leprince, Jean Chastre, Alain Combes, et al.

    Despite quick implementation of reperfusion therapies, a few patients with high-risk, acute, massive, pulmonary embolism (PE) remain highly hemodynamically unstable. Others have absolute contraindication to receive reperfusion therapies. Venoarterial-extracorporeal membrane oxygenation (VA-ECMO) might lower their right ventricular overload, improve hemodynamic status, and restore tissue oxygenation. ECMO-related complications and 90-day mortality were analyzed for 17 highly unstable, ECMO-treated, massive PE patients admitted to a tertiary-care center (2006–2015). Hospital- discharge survivors were assessed for long-term health-related quality of life. A systematic review of this topic was also conducted. Seventeen high-risk PE patients [median age 51 (range 18–70) years, Simplified Acute Physiology Score II (SAPS II) 78 (45–95)] were placed on VA-ECMO for 4 (1–12) days. Among 15 (82%) patients with pre-ECMO cardiac arrest, seven (41%) were cannulated during cardiopulmonary resuscitation, and eight (47%) underwent pre-ECMO thrombolysis. Pre-ECMO median blood pressure, pH, and blood lactate were, respectively: 42 (0–106) mmHg, 6.99 (6.54–7.37) and 13 (4–19) mmol/L. Ninety-day survival was 47%. Fifteen (88%) patients suffered in-ICU severe hemorrhages with no impact on survival. Like other ECMO-treated patients, ours reported limitations of all physical domains but preserved mental health 19 (4–69) months post-ICU discharge. VA-ECMO could be a lifesaving rescue therapy for patients with high-risk, acute, massive PE when thrombolytic therapy fails or the patient is too sick to benefit from surgical thrombectomy. Because heparin-induced clot dissolution and spontaneous fibrinolysis allows ECMO weaning within several days, future studies should investigate whether VA-ECMO should be the sole therapy or completed by additional mechanical clot-removal therapies in this setting.


  • Open Access

    Extracorporeal membrane oxygenation for pheochromocytoma-induced cardiogenic shock

    by Guillaume Hekimian, Fatima Kharcha, Nicolas Bréchot, Matthieu Schmidt, Cécile Ghander, Guillaume Lebreton, Xavier Girerd, Christophe Tresallet, Jean-Louis Trouillet, Pascal Leprince, et al.


  • Does this patient have VAP?

    by Jean Chastre, Charles-Edouard Luyt